return to news
  1. Sun Pharma Q1 Results: Net profit rises 40.2% to ₹2,835.6 crore, revenue up 6%

Market News

Sun Pharma Q1 Results: Net profit rises 40.2% to ₹2,835.6 crore, revenue up 6%

WhatsApp Image 2024-06-20 at 9.58.49 AM.jpeg

2 min read | Updated on August 01, 2024, 15:00 IST

Twitter Page
Linkedin Page
Whatsapp Page

SUMMARY

Sun Pharma reported a consolidated net profit of ₹2,835.6 crore for the latest June quarter, up 40.2% year-on-year (YoY) from ₹2,022.5 crore in the year-ago period.

Stock list

Sun_Pharma_FB.webp

Sun Pharma has gained 36.6% year-to-date and has risen 50.6% in the past year.

Pharma major Sun Pharmaceutical Industries shares were trading in the green after the company reported its financial results for the first quarter of the financial year 2024-25 on Thursday.

The stock was trading 0.2% higher at ₹1,723.4 on the NSE. It was trading at ₹1,721.7, up 0.2%, on the BSE

Sun Pharma Q1 results

The speciality generic pharmaceutical company reported a consolidated net profit of ₹2,835.6 crore for the latest June quarter, up 40.2% year-on-year (YoY) from ₹2,022.5 crore in the year-ago period.

Revenue from operations increased 5.9% to ₹12,652.7 crore in Q1 FY25, compared to ₹11,940.8 crore in the corresponding period last year.

Sun Pharma's EBITDA (earnings before interest, taxes, depreciation, and amortisation) stood at ₹3,607.6 crore (including other operating revenues), up 8.3% YoY. The EBITDA margin for the April-June quarter of FY25 was 28.5% vs 27.9% during Q1 FY24.

Formulation sales in India were ₹4,144.5 crore, up by 16.4%. "India formulation sales accounted for about 33.1% of total consolidated sales," the company said in an exchange filing.

Formulation sales in the United States were $466 million, accounting for more than 31.1% of total consolidated sales.

Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, said, "Sun has recently attained several milestones with the approval of Leqselvi in the US, the filing of Nidlegy in Europe, and the completion of the acquisition of Taro minority shares. These steps advance our innovative and generic business offerings and will help us serve patients better."

The stock has gained 36.6% year-to-date and has risen 50.6% in the past year.

Uplearn

About The Author

WhatsApp Image 2024-06-20 at 9.58.49 AM.jpeg
Kamal Joshi is a business journalist who covers industries, markets and IPOs. He is passionate about breaking news and enjoys playing tennis, where he loves flexing his backhand.

Next Story